Glenn Saldanha is the Chairman & Managing Director of Glenmark Pharmaceuticals Limited. He joined Glenmark Pharmaceuticals in 1998 as Director and took over as Managing Director & CEO in 2001.
He also holds a Bachelor’s Degree in Pharmacy from Mumbai University and holds an MBA from Leonard Stern School of Business, New York University. Prior to Glenmark, he has worked with Eli Lily, USA and Price water house Coopers, USA
As Chairman & Managing Director of Glenmark Pharmaceuticals Limited, Glenn Saldanha oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenue over a billion dollars and commercial presence in over 80 countries.
Under his leadership, Glenmark has evolved from an Indian branded generics business, into a research-driven and innovation-led organization. Glenn’s vision is to discover, develop and take to market India’s first innovative drug for the entire world.
The passion has clearly paid rich dividends. His father set up Glenmark – named after his two sons, Glenn and Mark, in 1977 with Rs 100,000 and three employees. In 1998, when Saldanha took charge the company had a turnover of Rs 70 crore with a strong presence in the domestic formulations market but almost negligible operations overseas.
Major achievements of Glenn Saldanha:-
- ‘Best CEO: Pharma & Healthcare’ by Business Today 2014
- ‘Top 50 CEOs in India’ by Entrepreneur Magazine in 2014
- ‘Swiss Ambassador’s Award for Exceptional Innovation’ –Embassy Switzerland 2012
- ‘Top 30 Youth Icons of India’2012 – Hindustan Times
- ‘Young Business Leader of the Year’ by UK Trade & Investment,2009
- India’s second most Valuable CEO – Business World, December 2008
During his tenure the biggest achievement for Glenmark has been its ability to discover best-in-class or first-in-class molecules for global development and medical needs for positioning Glenmark as a leader in drug Discovery.
Glenmark has managed to strike seven out licensing deals in Innovative R&D with big pharmaceutical companies. Presently, Glenmark has a strong pipeline of seven molecules in various stages of clinical and preclinical stages, all having potential in the range of USD 1 to 3 billion, if successfully commissioned. Glenn’s vision is to discover, develop and take to market India’s first innovative drug for the entire world.
Glenmark is one of India’s few companies involved in original drug research, with a seven molecule pipeline. Costs of drug development is inhibitive, so the Indian company needs to sell molecules it discovers in an out-licensing agreement with partners who can fund development till it is ready to be marketed. Glen mark’s expected to strike two such deals this financial year, but none has closed yet.